Targeting New Pathways in Alopecia Areata: The Role of JAK Inhibitors(ID: i818a)

1.How many years have you been in practice?(Required.)
2.How many patients with AA do you manage per week?  (Required.)
3.Please select the option that best describes your practice setting.(Required.)
4.After participating in this activity, how confident are you identifying patients with AA in your practice? (Required.)
5.After participating in this activity, how confident are you treating patients with AA in your practice?(Required.)
6.How committed are you to making changes in your practice based on your participation in this activity?(Required.)
7.After participating in this activity, which of the following domains do you plan to assess in patients with AA in your practice? Please select all that apply.(Required.)
8.Which of the following best describes the impact of this activity on your performance?(Required.)
9.Which new strategies/skills/information will you apply to your area of practice? Please select all that apply.(Required.)
10.What barriers do you see to making changes in your practice? Please select all that apply.(Required.)
11.Please rate your level of agreement by checking the appropriate rating.

After participating in today’s activity, I am now better able to:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Discuss the epidemiology of AA and the impact of this disease on patient QOL
Understand the clinical manifestations of AA to improve evaluation of disease severity
Employ strategies to individualize treatment for patients with AA
Summarize the pathophysiology of AA
Discuss emerging therapies for AA, including JAK inhibitors, JAK/TEC inhibitors, and clinical trial data
12.Please rate your level of agreement by checking the appropriate rating.

Brett King, MD, PhD, effectively:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Presented the Material
Avoided Commercial Bias
13.Please rate your level of agreement by checking the appropriate rating.

Brittany Craiglow, MD​, effectively:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Presented the material
Avoided commercial bias
14.Please rate your level of agreement by checking the appropriate rating.

Sergio Vañó Galván, MD, PhD​, effectively:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Presented the material
Avoided commercial bias
15.Please rate your level of agreement by checking the appropriate rating. 

The content presented:
(Required.)
Strongly agree
Agree
Neutral
Disagree
Strongly disagree
Enhanced my current knowledge base
Addressed my most pressing questions
Promoted improvements or quality in health care
Was scientifically rigorous and evidence based
Avoided commercial bias or influence
16.As a result of your participation in this activity, what is the one change you are most likely to implement in your practice?
17.Please list any clinical issues/problems within your scope of practice you would like to see addressed in future educational activities on AA:
18.If you indicated that you perceived commercial bias or influence, please describe:
Privacy & Cookie Notice